Results 41 to 50 of about 19,474 (223)

Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas

Nature
H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the disialoganglioside GD2 (ref. 1). Chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) eradicated DMGs in preclinical models1. Arm A of Phase I trial no.
Michelle Monje, Jasia Mahdi, R. Majzner, Kristen W. Yeom, Liora M. Schultz, R. Richards, Vali Barsan, Kun-Wei Song, Jennifer Kamens, C. Baggott, Michael Kunicki, Skyler P. Rietberg, A. S. Lim, Agnes Reschke, Sharon A. Mavroukakis, E. Egeler, J. Moon, Shabnum Patel, Harshini Chinnasamy, C. Erickson, Ashley Jacobs, Allison K. Duh, R. Tunuguntla, D. Klysz, C. Fowler, S. Green, Barbara Beebe, Casey Carr, M. Fujimoto, A. Brown, Ann-Louise G Petersen, Catherine McIntyre, Aman Siddiqui, Nadia Lepori-Bui, Katlin Villar, Kymhuynh Pham, R. Bove, Eric Musa, Warren D. Reynolds, Adam Kuo, Snehit Prabhu, Lindsey Rasmussen, Tim Cornell, S. Partap, P. Fisher, C. Campen, Gerald Grant, L. Prolo, Xiao-Bu Ye, B. Sahaf, KL Davis, Steven A. Feldman, S. Ramakrishna, Crystal Mackall   +53 more
semanticscholar   +1 more source

Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins

, 2021
Gangliosides have been considered to modulate cell signals in the microdomain of the cell membrane, lipid/rafts, or glycolipid-enriched microdomain/rafts (GEM/rafts).
Farhana Yesmin, Robiul H. Bhuiyan, Tetsuya Okajima, Keiko Furukawa, Norihiro Kotani, Pu Zhang, Kei Kaneko, Yuhsuke Ohmi, Kazunori Hamamura, Satoko Yamamoto, Yuki Ohkawa, Nai-Kong V. Cheung, Orie Tajima, Koichi Honke, Koichi Furukawa, Mariko Kambe   +15 more
core   +1 more source

Intermediary filament and GD2-expression in astrocytic tumors

, 2011
In der Arbeit wird eine vergleichende, semiquantitative immunhistochemische Untersuchung der Expression von saurem Gliafaserprotein, Vimentin und Glykosphingolipid GD2 in 28 astrozytären Hirntumoren WHO Grad II-IV dargestellt.
Lell, Barbara
core   +2 more sources

Overall review of curative impact and barriers of CAR-T cells in osteosarcoma

EXCLI Journal : Experimental and Clinical Sciences
Osteosarcoma (OS) is a rare form of cancer and primary bone malignancy in children and adolescents. Current therapies include surgery, chemotherapy, and amputation.
Guilin Li, Hong Wang, Vafa Meftahpour
doaj   +1 more source

Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. [PDF]

PLoS ONE, 2015
Ganglioside GD2 is a plasma membrane glycosphinogolipid. In healthy adults it is expressed at low levels, but it is over-expressed in many cancers. For cancer therapy, GD2 is targeted with anti-GD2 monoclonal antibodies (mAbs), and one adverse side ...
Wenyong Tong, Mario Maira, Martin Gagnon, H Uri Saragovi   +3 more
doaj   +1 more source

Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15

Journal for ImmunoTherapy of Cancer
The ability of immune cells to expand numerically after infusion distinguishes adoptive immunotherapies from traditional drugs, providing unique therapeutic advantages as well as the potential for unmanageable toxicities.
Geng-Wen Tian, Amy N. Courtney, Hang-Jin Yu, S. Bhar, Xin Xu, Gabriel A. Barragán, Claudia Martinez Amador, Nisha Ghatwai, Michael S. Wood, D. Schady, A. Montalbano, Shantan Reddy, A. Roche, Davi de Lacerda, Donald Williams Parsons, Erica J. Di Pierro, Frederic D. Bushman, A. Heczey, L. Metelitsa   +18 more
semanticscholar   +1 more source

Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models

Neuro-Oncology
Background Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy ...
Jessica B. Foster, Peter J. Madsen, Kyra Harvey, C. Griffin, A. Stern, Luke Patterson, N. Joshi, Conor Dickson, Olivia Mcmanus, Ezra Beaubien, Cullen Wilson, David R. Beale, V. Baubet, Peeyush N. Goel, N. Vitanza, J. Nazarian, M. Koptyra, P. Storm, Adam C. Resnick   +18 more
semanticscholar   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Flow cytometric analysis of GD2 expression in canine and human tumor cells.

, 2021
Thick black line indicates cells positively stained with anti-GD2-PE (clone 14.G2a, a murine IgG2a anti-GD2 mAb) and grey shaded areas indicate FMO control. Values indicate percent GD2+ cells. 17CM98, CML-6M and CML-1 are canine melanoma cell lines.
Zachary S. Morris (6287090), Christine Jaskowiak (11268701), Eduardo Aluicio-Sarduy (1610008), Ilene D. Kurzman (11268692), Joseph Grudzinski (11268689), Jonathan W. Engle (325235), Elizabeth A. Oseid (11268698), Michelle M. Turek (11268686), Mark R. Albertini (11268704), David M. Vail (11268710), Paul M. Sondel (5408369), Kara Magee (11268683), Cindy L. Zuleger (11268695), Karla Esbona (3580781), Reinier Hernandez (1329030), Ian R. Marsh (3041166), Bryan Bednarz (11268707), Jamey P. Weichert (400808)   +17 more
core   +1 more source

Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study

Cancers
Simple Summary High-risk neuroblastoma is a childhood cancer with poor survival rates despite intensive treatment. Adding anti-GD2 immunotherapy to standard therapies has improved survival, but little is known about the long-term effects (of the anti-GD2-
T. Flaadt, Jonas Rehm, T. Simon, Barbara Hero, R. Ladenstein, Holger N. Lode, D. Grabow, S. Nolte, R. Crazzolara, J. Greil, M. Ebinger, M. Abele, Ursula Holzer, M. Döring, Johannes H. Schulte, P. Bader, P. Schlegel, M. Eyrich, Peter Lang, T. Klingebiel, R. Handgretinger   +20 more
semanticscholar   +1 more source